Classifying prostate cancer subtypes from liquid biopsies

A set of computational tools to accurately classify metastatic castration-resistant prostate cancer subtypes from ctDNA.

Liquid biopsy‐based targeted gene screening highlights tumor cell ...

Prostate cancer (PCa) clinical heterogeneity underscores tumor heterogeneity, which may be best defined by cell subtypes.

Blood-based liquid biopsies for prostate cancer: clinical ... - Nature

ctDNA analysis of metastatic prostate cancer patients is able to identify prostate cancer genomic features. When the circulating tumour fraction ...

Liquid Biopsies as a Tool to Combat Prostate Cancer - Norgen Biotek

... cancer patients, as well as the specific tumor type and subtype. Interestingly, the classification model worked best for prostate cancer ...

Prostate cancer and liquid biopsies: Clinical applications ... - PubMed

Cell-free DNA and extracellular vesicle analysis have demonstrated promise in diagnosis, prognostication, assessment of treatment responses, and identification ...

Liquid biopsy epigenomic profiling for cancer subtyping - Nature

Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability ...

Current Advances of Liquid Biopsies in Prostate Cancer - Cell Press

Recently, ncRNA, ctDNA/RNA, exosomes, and metabolomic biomarkers in the LBs of PCa patients showed significant differences and clinical benefits ...

Hutch News | Fred Hutchinson Cancer Center

Classifying prostate cancer subtypes from liquid biopsies. From the Ha and Nelson labs, Human ...

Practical Utility of Liquid Biopsies for Evaluating Genomic Alterations ...

This study suggests that a liquid biopsy can be a good option for checking gene changes in advanced prostate cancer patients.

Prostate cancer and liquid biopsies: Clinical applications and ...

Liquid biopsy involves the analysis of circulating biomarkers, such as circulating tumor DNA (ctDNA) and extracellular vesicles (EVs), shed into ...

Current advances of liquid biopsies in prostate cancer - Cell Press

Recently, non-coding RNA (ncRNA), circulating tumor DNA (ctDNA)/ctRNA, exosomes, and metabolomic biomarkers in the liquid biopsies (LBs) of ...

Current advances of liquid biopsies in prostate cancer: Molecular ...

Additionally, the expression of miR-19a and miR-19b in urine biopsy can be used as a prognostic biomarker for BRC in treated patients. Such signals can classify ...

The role of liquid biopsies in prostate cancer management

The common liquid biopsy biomarkers are circulating tumor cells (CTCs), extracellular vesicles (EVs), and circulating tumor DNA (ctDNA). Each biomarker provides ...

Clinical factors associated with successful liquid tumor biopsy in ...

Background: Liquid biopsies using cell-free DNA (cfDNA) can be used in prostate cancer (PrCa) patients when tissue is unavailable and repeat ...

Genome-wide studies in prostate cancer poised liquid biopsy as a ...

Recent genome-wide liquid biopsy studies in prostate cancer analyzing plasma samples have provided insights into the genome and epigenome dynamics during ...

Identifying and analyzing different cancer subtypes using RNA-seq ...

The Potential of Circulating Tumor Cells as a Liquid Biopsy to Guide Therapy in Prostate Cancer. Cancer discovery. 2012; 2:974-975. 26 ...

Liquid Biopsy: Catching Cancer Cells in the Blood

Unlike other blood tests (such as the 4K score or PHI, which look for certain biomarkers of prostate cancer), or germline genetic tests (which ...

Liquid biopsy: a step closer to transform diagnosis, prognosis and ...

Liquid biopsies consist of isolating tumor-derived entities like circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, ...

Nucleosome Patterns in Circulating Tumor DNA Reveal ...

Comprehensive Resource of Matched Tumor and Liquid Biopsies from PDX Models of Advanced Prostate Cancer. To develop approaches for the accurate classification ...

The role of liquid biopsies in prostate cancer management

The common liquid biopsy biomarkers are circulating tumor cells (CTCs), extracellular vesicles (EVs), and circulating tumor DNA (ctDNA). Each ...